Blog

Using Artificial Intelligence to Optimise Small-Molecule Drug Design

Here at BenevolentAI, we are unlocking the power of scientific data so no disease goes untreated.

We achieve this in a variety of ways, right from initial target identification and validation, through hit discovery and lead optimisation, and finally into the clinic, making us the only end-to-end drug discovery company driven by Artificial Intelligence (AI) in the world.

We power this innovation by using structured and unstructured data sources to learn new insights and relationships at scale that otherwise would not be possible. Here, a key differentiator is how we use AI to extract the knowledge locked in the scientific literature and patents to boost our knowledge graph of entity relationships of genes, targets, molecules, and diseases.

My role at BenevolentAI, as head of the Chemoinformatics team, is to guide the scientific direction and validity in the development of our molecular design platform. The size of drug-like chemistry space is truly vast. As an analogy, if we take six Lego bricks, it is possible to construct them in almost one billion unique configurations. Replacing the bricks for atoms, and scaling the number up from six to the more typical size of a drug-like molecule of 20-30 heavy atoms, the size of the space expands dramatically to truly astronomical proportions. The size of this space makes it technically challenging to exhaustively examine every theoretical molecule, instead we use advanced AI algorithms to effectively sample that space to explore and exploit the most promising candidates to take to synthesis and testing.

Drug discovery itself is an inherently multiobjective optimisation process, with many different parameters needed to be optimised in concert. We score each of the candidate solutions with multiple predictive models using a range of appropriate parameters, including the introduction of synthetic tractability, and even planning synthetic routes.

The platform we have developed at BenevolentAI gives us the power to not only tell our scientists what to make, but also how to make the molecules that are of most relevance to our drug discovery programmes, thereby helping to optimise the whole of our AI-driven drug discovery pipeline.

More Posts

You Might Also Like

Blog
Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job
At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.
Oct 17, 2021
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Blog
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Blog
Expert-augmented computational drug discovery for rare diseases
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
Sep 28, 2021
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
Sep 9, 2021
Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021